The Cancer Research Institute funds the full spectrum of immunotherapy research, from lab to clinic to cure—making maximum impact on the future of cancer treatment.
Working in tandem with our global network of researchers, supporters, patients, and advocates, we're funding the best scientists doing the most promising research—all while promoting awareness, sharing up-to-date immunotherapy information, and inspiring lifelong advocacy for the cause.
We support the science behind the treatment, funding lifesaving immunotherapy research and clinical trials around the world.
Meet Our Scientists
Your trusted resource for the latest credible, accurate cancer immunotherapy information for scientists, patients, and supporters.
Learn How Immunotherapy Works
Join us in the cause to cure all cancers, advancing immunotherapy through events and awareness campaigns.
Create a Fundraising Team
Connecting you to an inspiring network of patients and advocates—that's a crucial part of our mission. See real stories of immunotherapy experiences, or share your own with others looking for insight and information.
Meet Your ImmunoCommunity
We are the Cancer Research Institute, a 501(c)(3) nonprofit organization dedicated to harnessing our immune system's power to control and potentially cure all types of cancer. We fund the most innovative clinical and laboratory research around the world, support the next generation of the field's leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers.
We're working for you—all of our supporters, patients, and scientists—to make the biggest impact possible in our efforts to cure cancer.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, 4th Floor | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
CRI scientists Dr. Michele Ardolino and Dr. David Raulet showed that Natural Killer cells can help eliminate tumors after checkpoint immunotherapy treatment even in the absence of T cells.
The third installment of the Rational Combinations 360 conference, which will be held in Philadelphia September 13-14, seeks to improve the design and application of combination immunotherapies for patients